Eli Lilly and Company (NYSE:LLY) Shares Sold by Fullerton Fund Management Co Ltd.

Fullerton Fund Management Co Ltd. reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 13.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 31,202 shares of the company's stock after selling 4,828 shares during the quarter. Eli Lilly and Company comprises about 0.8% of Fullerton Fund Management Co Ltd.'s holdings, making the stock its 29th largest position. Fullerton Fund Management Co Ltd.'s holdings in Eli Lilly and Company were worth $24,088,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Highline Wealth Partners LLC grew its holdings in Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares during the last quarter. FPC Investment Advisory Inc. increased its position in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $58,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LLY. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,002.80.

Eli Lilly and Company Stock Down 3.9%

Shares of LLY traded down $29.33 during mid-day trading on Wednesday, reaching $716.73. 3,856,706 shares of the stock traded hands, compared to its average volume of 3,552,858. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm has a market cap of $679.27 billion, a price-to-earnings ratio of 61.21, a P/E/G ratio of 1.40 and a beta of 0.48. The stock has a fifty day simple moving average of $804.15 and a 200 day simple moving average of $808.91.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.